Psychosis in Dementia Conclusions Psychosis in dementia is distressful and disturbing to patients and  Is similar across the spectrum of the dementia.

Slides:



Advertisements
Similar presentations
DEPRESSION IN ELDERLY CAREGIVERS OF PATIENTS WITH ALZHEIMER'S DISEASE: WHAT DOES IT DEPEND ON? Department of Alzheimer's disease and related disorders.
Advertisements

Methods for Studies in Preventing Cognitive Loss and Dementia
The Australian Imaging Biomarkers and Lifestyle Flagship Study of Ageing AUSTRALIAN ADNI. July 2010 UPDATE.
The FREEDOM Study (Impact of Short Daily Hemodialysis on Restless Legs Symptoms and Sleep Disturbances) Source Jaber BL, Schiller B, Burkart JM, et al.
Living well with dementia: more timely diagnosis and early intervention Louise Robinson Professor of Primary Care and Ageing RCGP National Clinical Champion.
New England Journal of Medicine October 18;367: Relapse Risk after Discontinuation of Risperidone in Alzheimer’s disease Molly Moncrieff.
Long term effect of self-regulation education on use of inhaled anti-inflammatories and short-acting bronchodilators Clark, NM, Gong, M, Wang, S, Lin,
Characteristics of Arizona Physicians Reentering Clinical Practice Mary Ellen Rimsza, MD FAAP Physician Reentry into the Workforce Conference.
Clinical trials with DeNDRoN in the North East Dr Margaret Piggott Data and Communications Manager Dementias and Neurodegenerative.
Tony WAEGEMANS, MD UCB Pharma, Belgium. TW/ll/ Washington/MCI 2 MCI as implemented in our study MCI is a very early stage of dementia with as main.
Lucy Wang, M.D.. A 74 year old veteran with Alzheimer’s disease is referred for assistance in managing agitation. He is living in a nursing home, and.
Noreen Clark, PhD Molly Gong, MD Julie Dodge, MS Sijian Wang, M.S. Xihong Lin, PhD William Bria, MD Timothy Johnson, MD University of Michigan School of.
Treatment Options for Dementia Deb Bynum, MD Division of Geriatric Medicine University of North Carolina.
MCI Clinical Trial Design FDA Advisory Committee Meeting March 13, 2001 Gaithersburg, MD Michael Grundman, MD, MPH Alzheimer’s Disease Cooperative Study.
GAL-INT-6 The safety and efficacy of galantamine in patients with Vascular dementia or AD with cerebrovascular disease Sean Lilienfeld MD, FCP, MMed Janssen.
Will we ever have effective treatments for dementia? Robert Howard King’s College London
PAIN MANAGEMENT AND THE IMPACT OF PAIN ON QUALITY OF LIFE IN NURSING HOME RESIDENTS Efrat Adler, RN, MS, FNP, Doctoral Student 1,2 Ann L. Gruber-Baldini,
Alzheimer’s patients Caregivers Survey in Greece Dr Paraskevi Sakka Neuropsychiatrist Chairwoman, Athens Association of Alzheimer’s Disease and Related.
Cognitive Impairment: An Independent Predictor of Excess Mortality SACHS, CARTER, HOLTZ, ET AL. ANN INTERN MED, SEP, 2011;155: ZACHARY LAPAQUETTE.
Epidemiology of Dementia: the MoVIES Project Alzheimer’s Disease Patient Registry (ADPR ), University of Pittsburgh Initially funded by NIA under.
Specific functional effects of memantine treatment in patients with moderate to severe Alzheimer’s disease Doody R., Wirth Y., Schmitt F. and Möbius H.J.
Using an Evidence Based Practice Approach to Plan Treatment for Individuals over 65 Seeking Treatment for Depression in an Adult Psychiatry Clinic Colleen.
Memantine in Vascular Dementia Möbius H.J. and Stöffler A. International Psychogeriatrics 2003, 15 Suppl 1:
Non-pharmacologic Management There is good evidence to recommend an individualized exercise program for patients with mild to moderate dementia – A simple.
Alzheimer Care Centre Long-Term Data Set Walsh, T. L., Milke, D. L. & George, C.P. In June 2002, as part of a five-year research plan, CapitalCare initiated.
1 Patient Dependence, Function, and Changes in Cost of Care in Alzheimer’s Disease Carolyn W. Zhu JJP VA Medical Center, Mount Sinai School of Medicine.
Mental and Behavioral Disorders 1. Mental, Behavioral and Neurodevelopment Disorders (F01- F99)  Codes in this chapter include disorders of psychosocial.
Meredith Cook – PharmD Candidate Mercer University COPHS August, 2012 Cognitive Trajectories after Postoperative Delirium.
Why Physicians Do Not Diagnose Alzheimer’s Disease Mark A. Sager, MD Professor of Medicine and Population Health Sciences Director, Wisconsin Alzheimer’s.
Alan Breier, M.D. Leader, Zyprexa Product Team Lilly Research Fellow Professor of Psychiatry, Indiana University School of Medicine Adjunct Associate of.
Alzheimer’s Disease  Goals  To understand what dementia is  To explore causes, risk factors, symptoms, and treatments of Alzheimer’s Disease  To better.
Observed Ward Behavior Strongly Associated with Real World Living Skills: An Analysis of Concurrent Validity between NOSIE and ILSI Charlie A. Davidson,
Specialised Geriatric Services Heather Gilley Sharon Straus.
Improvement in behavioural symptoms in patients with moderate to severe Alzheimer’s disease (AD) by memantine: a pooled data analysis Gauthier S., Loft.
Do Instrumental Activities of Daily Living Predict Dementia at 1- and 2- Year Follow-Up? Findings from the Development of Screening Guidelines and Diagnostic.
OLD AGE PSYCHIATRY FOR PRIMARY CARE VOCATIONAL TRAINEES Dr Nick Pearson Consultant in the Psychiatry of Old Age Reading
Lecture 9: Analysis of intervention studies Randomized trial - categorical outcome Measures of risk: –incidence rate of an adverse event (death, etc) It.
Adverse Outcomes After Hospitalization and Delirium in Persons with Alzheimer Disease Charles Wang, PharmD Candidate.
Which factors predict outcome in the nonoperative treatment of patellofemoral pain syndrome? A prospective follow-up study Kannus P, Nittymaki S. Med.
Once Weekly Spaced Retrieval Training can Lead to Learning in People with Dementia. Chris Materne, Mary Luszcz & Malcolm Bond.
CC-1 Benefit-Risk Assessment Murat Emre, MD Professor of Neurology Istanbul Faculty of Medicine Department of Neurology Behavioral Neurology and Movement.
Journal of the American Medical Association (JAMA), 2004, 291:
Optimization of psychotropic drug prescription in nursing home patients with dementia: the PROPER study (PRescription Optimization of Psychotropic drugs.
Thank You This PowerPoint document contains the images that you requested. Copyright Notice All Online Service materials, including, without limitation,
CS-1 Regulatory Considerations: PDD Indication for Exelon ® (rivastigmine) Martina Struck, PhD Senior Associate Director Drug Regulatory Affairs Novartis.
Effects of Memantine on behavioural symptoms in Alzheimer’s disease patients: an analysis of the Neuropsychiatric Inventory (NPI) data of two randomised,
Used to be called Dementia Neurocognitive Disorders.
Mild Cognitive Impairment, Activity Participation, Functional Difficulty, and Adaptations in Functionally Vulnerable Elderly People: A Closer Look Laraine.
Memantine (Ebixor) Joanne Lily Wombwell Senior Memory Clinic Nurse Hartington Unit, CNDRH.
Dementia diagnosis doorway Dr Ethie Kong GP and Chair of NHS Brent #BigBrentDebate.
Neurologic Effects Associated With Efavirenz Generally Mild, Transient Slideset on: Clifford DB, Evans S, Yang Y, et al. Impact of efavirenz on neuropsychological.
Music therapy in moderate and severe dementia of Alzheimer’s type: a case-control study H.B. Svansdottir and J. Snaedal Geriatric Department, Landspitali.
Date of download: 7/8/2016 Copyright © 2016 American Medical Association. All rights reserved. From: Intranasal Insulin Therapy for Alzheimer Disease and.
Aka STEEL VALLEY SENIORS SURVEY (SVSS)
M. M. Dumitru¹∙², V.Chirita¹∙², R.Chirita¹∙²
The behavioral pathology in Alzheimer's Disease Scale; BEHAVE-AD
Volume 3, Issue 1, Pages 1-9 (January 2017)
Eli Lilly’s Experimental Alzheimer’s Drug Fails in Large Trial
Expert Perspectives on New Treatment Options for Parkinson Disease Psychosis.
Epidemiology of Dementia: the MoVIES Project
Polypharmacy and specific medication profiles as predictors of treatment and health outcomes in dementia Dr Christoph Mueller, NIHR Academic Clinical Lecturer.
MM McDermott and coauthors
Early Dementia Distinguishing AD From MCI
11/30/2018 Using Delayed Start Design and Analysis to Investigate Potential Disease Modifying Effects in Alzheimer’s Disease.
Staff Distress Improves by Treating Pain in Nursing Home Patients With Dementia: Results From a Cluster-Randomized Controlled Trial  Irene Aasmul, MSN,
Efficacy and safety of niacin/laropiprant
Baseline Characteristics of the Subjects
Baseline demographics and clinical characteristics of 3,956 rosuvastatin-treated patients Donald G. Vidt, et al. Am J Cardiol 2006;97:1602–1606.
Phase 3 solanezumab trials: Secondary outcomes in mild Alzheimer's disease patients  Eric R. Siemers, Karen L. Sundell, Christopher Carlson, Michael Case,
Fig. 1. ROC curve for K-IADL to diagnose dementia or MCI
Presentation transcript:

Psychosis in Dementia Conclusions Psychosis in dementia is distressful and disturbing to patients and  Is similar across the spectrum of the dementia  Is common  Can be identified  Is persistent

Psychosis in Dementia Methods Janssen has 2 databases of 1603 patients:  Data contains information from 2 studies:  Mild to moderate AD, community-dwelling  Severe AD, nursing home residents  The placebo data from these trials describes a natural history of psychosis in AD (n=285); (n=162) What was done with the data:  Experts correlated scale-items and item-scores with their clinical experience to identify characteristics of AD patients with psychosis  Delusions/hallucinations subscales: NPI of 4 or greater or BEHAVE- AD of 2 or greater

Mild to Moderate AD, community dwelling (n=285) Severe AD, nursing home (n=162) Women = 62% Mean age = 77 years Mean MMSE = % had AD Women = 67% Mean age = 83 years Mean MMSE = 7 Psychosis in Dementia Demographics 84% had AD

Psychosis in Dementia Community Based & Nursing Home Residents with Alzheimer’s Disease ~7 in 10 nursing home residents had psychosis during the study ~2 in 10 community dwelling AD patients had psychosis during the study

Psychosis in Dementia Results Community Dwelling (n=285) Nursing Home (n=162)  12% had psychosis at baseline  2/3 had symptoms that persisted for at least 1 month  1/3 had symptoms that persisted for at least 5 months  12% developed a psychosis  64% had psychosis at baseline  >2/3 had symptoms that persisted for at least 2 weeks  1/2 had symptoms that persisted for at least 4 weeks  17% developed a psychosis

Psychosis in Dementia Conclusions Psychosis in dementia is distressful and disturbing to patients and  Is similar across the spectrum of the dementia  Is common  Can be identified  Is persistent